Literature DB >> 26935987

Sulforaphane inhibits TGF-β-induced epithelial-mesenchymal transition of hepatocellular carcinoma cells via the reactive oxygen species-dependent pathway.

Jinsheng Wu1, Jingli Han2, Benxin Hou3, Chengwei Deng1, Huanliang Wu1, Liangfang Shen4.   

Abstract

Sulforaphane is recognized as a safe antitumor agent derived from various cruciferous vegetables, including broccoli. It has been demonstrated that sulforaphase is a potent antitumor agent in diverse cancers. However, its effect on hepatocellular carcinoma remains largely unknown. Here, we show that sulforaphane inhibits TGF-β-induced epithelial-mesenchymal transition of hepatocellular carcinoma cell via the reactive oxygen species-dependent pathway. We found sulforaphane inhibited hepatocellular carcinoma cell proliferation in a dose- and time-dependent manner. Sulforaphane induced G0/G1 phase cell cycle arrest and promoted cell apoptosis. A set of experiments showed that sulforaphase inhibited hepatocellular carcinoma cell migration and invasion, inhibited the formation of fibroblast like mesenchymal cells and the expression of Vimentin, but increased the expression of E-cadherin, suggesting sulforaphane suppresses epithelial-mesenchymal transition (EMT) process. Cotreatment with N-acetyl-L-cysteine inhibited sulforaphane-inhibited invasion and upregulation of E-cadherin and almost completely abolished the sulforaphane-induced expression of Vimentin. The effect of sulforaphane on the growth of hepatocellular carcinoma cells was confirmed by a xenograft tumor growth model. All our finding indicated that sulforaphane is a promising and safe strategy for treating hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26935987     DOI: 10.3892/or.2016.4638

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Effects of the isothiocyanate sulforaphane on TGF-β1-induced rat cardiac fibroblast activation and extracellular matrix interactions.

Authors:  Charity Fix; Amanda Carver-Molina; Mrinmay Chakrabarti; Mohamad Azhar; Wayne Carver
Journal:  J Cell Physiol       Date:  2019-01-04       Impact factor: 6.384

2.  Current potential health benefits of sulforaphane.

Authors:  Jae Kwang Kim; Sang Un Park
Journal:  EXCLI J       Date:  2016-10-13       Impact factor: 4.068

3.  An update on diabetic kidney disease, oxidative stress and antioxidant agents.

Authors:  Leila Mahmoodnia; Esmat Aghadavod; Sara Beigrezaei; Mahmoud Rafieian-Kopaei
Journal:  J Renal Inj Prev       Date:  2017-01-20

Review 4.  Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β.

Authors:  Yutaro Tsubakihara; Aristidis Moustakas
Journal:  Int J Mol Sci       Date:  2018-11-20       Impact factor: 5.923

Review 5.  Validation of Hepatocellular Carcinoma Experimental Models for TGF-β Promoting Tumor Progression.

Authors:  Serena Mancarella; Silke Krol; Alberto Crovace; Stefano Leporatti; Francesco Dituri; Martina Frusciante; Gianluigi Giannelli
Journal:  Cancers (Basel)       Date:  2019-10-09       Impact factor: 6.639

Review 6.  Reversal of Epithelial-Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids.

Authors:  Chang Hoon Lee
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

7.  Effects of sulforaphane on cognitive function in patients with frontal brain damage: study protocol for a randomised controlled trial.

Authors:  Fangkun Liu; Jing Huang; Gangrui Hei; Renrong Wu; Zhixiong Liu
Journal:  BMJ Open       Date:  2020-10-16       Impact factor: 2.692

Review 8.  Mechanisms of TGFβ-Induced Epithelial-Mesenchymal Transition.

Authors:  Aristidis Moustakas; Carl-Henrik Heldin
Journal:  J Clin Med       Date:  2016-06-29       Impact factor: 4.241

9.  Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling.

Authors:  Peng Liu; Samuel J Atkinson; Sophia E Akbareian; Zhigang Zhou; Andrea Munsterberg; Stephen D Robinson; Yongping Bao
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

Review 10.  Emerging Targets in Type 2 Diabetes and Diabetic Complications.

Authors:  Sevgican Demir; Peter P Nawroth; Stephan Herzig; Bilgen Ekim Üstünel
Journal:  Adv Sci (Weinh)       Date:  2021-07-28       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.